Ascendis Pharma (NASDAQ:ASND) is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. The company's operations are centered on its proprietary TransCon technology, which enables the creation of new and improved versions of existing drugs, aiming to provide enhanced clinical efficacy, safety, and patient experience. Ascendis has a diverse portfolio of projects, spanning areas such as endocrinology, oncology, and other major therapeutic fields. Its objective is to leverage its technology platform to build a leading, sustainable biopharma company that brings meaningful improvements to patients' lives worldwide.